Treatment of indinavir sulfate induced urolithiasis in HIV-positive patients.
Indinavir sulfate is a protease inhibitor used of the treatment of primary HIV infection either as monotherapy or as part of antiretroviral treatment schemes. Approximately 10% of all patients develop urolithiasis with radiolucent stones consisting of indinavir. We present our results of the treatment in 11 HIV positive patients (9 men, 2 women), who developed Indinavir lithiasis after 5-8 months of antiretroviral therapy. Following the initial procedures (spasmoanalgetic drugs, ureteroscopy, double J-stent or nephrostomy), the patients were further treated by increasing diuresis and urinary acidification. All the patients responded well to the treatment, the obstruction was releieved and their renal function was restored to normal.
Kalaitzis
Christos
C
Department of Urology, Democritus University of Thrace, Alexandroupolis, Greece.
Dimitriadis
Georgios
G
Tsatidis
Triantafylos
T
Kuntz
Rainer
R
Touloupidis
Stavros
S
Kelidis
Georgios
G
D000328:Adult; D005260:Female; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006679:HIV Seropositivity / Q000188:drug therapy*; D006801:Humans; D019469:Indinavir / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D014545:Urinary Calculi / Q000139:chemically induced* / Q000628:therapy
D017320:HIV Protease Inhibitors; D019469:Indinavir